Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer

Katsuyuki Hotta, Nagio Takigawa, Katsuyuki Kiura, Masahiro Tabata, Shigeki Umemura, Atsuko Ogino, Akiko Uchida, Akihiro Bessho, Yoshihiko Segawa, Tetsu Shinkai, Naoyuki Nogami, Shingo Harita, Niro Okimoto, Hiroshi Ueoka, Mitsune Tanimoto

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Combination chemotherapy of irinotecan and amrubicin for advanced non-small cell lung cancer (NSCLC) has not been fully evaluated. To determine the maximum-tolerated dose (MTD), a phase I study in patients with advanced NSCLC was conducted. Materials and Methods: Patients with stage IIIB/IV NSCLC were enrolled in this study. Both patients with and without prior chemotherapy were also eligible. The drugs were administered on days 1 and 8, every 3 weeks. The starting doses of irinotecan and amrubicin were 60 and 35 mg/m2, respectively. Results: Nineteen patients received a total of 53 courses. Grade 4 neutropenia was observed in 23% of courses. Anaemia and thrombocytopenia were generally mild. Grade 3 febrile neutropenia occurred in 5 courses. Other grade 3 or greater non-haematological toxicities were observed in only 4 out of 52 courses (grade 3 infection and hyponatremia). The maximum-tolerated doses (MTDs) of irinotecan and amrubicin were 100 and 45 mg/m , respectively. Objective response was obtained in 2 patients (10.5%), who had received prior chemotherapy. Conclusion: This combination was well tolerated, but produced only a modest anti-tumour effect for advanced NSCLC. Further investigation into the role of this regimen as a salvage chemotherapy may be warranted in relapsed patients.

Original languageEnglish
Pages (from-to)2429-2434
Number of pages6
JournalAnticancer Research
Volume25
Issue number3 C
Publication statusPublished - May 2005

Fingerprint

irinotecan
Non-Small Cell Lung Carcinoma
Maximum Tolerated Dose
Drug Therapy
Febrile Neutropenia
Hyponatremia
Combination Drug Therapy
Neutropenia
Thrombocytopenia
amrubicin
Anemia

Keywords

  • Amrubicin
  • Irinotecan
  • Non-platinum regimen
  • Non-small cell lung cancer
  • Phase I study
  • Topoisomerase inhibitor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer. / Hotta, Katsuyuki; Takigawa, Nagio; Kiura, Katsuyuki; Tabata, Masahiro; Umemura, Shigeki; Ogino, Atsuko; Uchida, Akiko; Bessho, Akihiro; Segawa, Yoshihiko; Shinkai, Tetsu; Nogami, Naoyuki; Harita, Shingo; Okimoto, Niro; Ueoka, Hiroshi; Tanimoto, Mitsune.

In: Anticancer Research, Vol. 25, No. 3 C, 05.2005, p. 2429-2434.

Research output: Contribution to journalArticle

Hotta, K, Takigawa, N, Kiura, K, Tabata, M, Umemura, S, Ogino, A, Uchida, A, Bessho, A, Segawa, Y, Shinkai, T, Nogami, N, Harita, S, Okimoto, N, Ueoka, H & Tanimoto, M 2005, 'Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer', Anticancer Research, vol. 25, no. 3 C, pp. 2429-2434.
Hotta, Katsuyuki ; Takigawa, Nagio ; Kiura, Katsuyuki ; Tabata, Masahiro ; Umemura, Shigeki ; Ogino, Atsuko ; Uchida, Akiko ; Bessho, Akihiro ; Segawa, Yoshihiko ; Shinkai, Tetsu ; Nogami, Naoyuki ; Harita, Shingo ; Okimoto, Niro ; Ueoka, Hiroshi ; Tanimoto, Mitsune. / Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer. In: Anticancer Research. 2005 ; Vol. 25, No. 3 C. pp. 2429-2434.
@article{8b04cf9f3beb4a9ca56799e5a9763a7d,
title = "Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer",
abstract = "Background: Combination chemotherapy of irinotecan and amrubicin for advanced non-small cell lung cancer (NSCLC) has not been fully evaluated. To determine the maximum-tolerated dose (MTD), a phase I study in patients with advanced NSCLC was conducted. Materials and Methods: Patients with stage IIIB/IV NSCLC were enrolled in this study. Both patients with and without prior chemotherapy were also eligible. The drugs were administered on days 1 and 8, every 3 weeks. The starting doses of irinotecan and amrubicin were 60 and 35 mg/m2, respectively. Results: Nineteen patients received a total of 53 courses. Grade 4 neutropenia was observed in 23{\%} of courses. Anaemia and thrombocytopenia were generally mild. Grade 3 febrile neutropenia occurred in 5 courses. Other grade 3 or greater non-haematological toxicities were observed in only 4 out of 52 courses (grade 3 infection and hyponatremia). The maximum-tolerated doses (MTDs) of irinotecan and amrubicin were 100 and 45 mg/m , respectively. Objective response was obtained in 2 patients (10.5{\%}), who had received prior chemotherapy. Conclusion: This combination was well tolerated, but produced only a modest anti-tumour effect for advanced NSCLC. Further investigation into the role of this regimen as a salvage chemotherapy may be warranted in relapsed patients.",
keywords = "Amrubicin, Irinotecan, Non-platinum regimen, Non-small cell lung cancer, Phase I study, Topoisomerase inhibitor",
author = "Katsuyuki Hotta and Nagio Takigawa and Katsuyuki Kiura and Masahiro Tabata and Shigeki Umemura and Atsuko Ogino and Akiko Uchida and Akihiro Bessho and Yoshihiko Segawa and Tetsu Shinkai and Naoyuki Nogami and Shingo Harita and Niro Okimoto and Hiroshi Ueoka and Mitsune Tanimoto",
year = "2005",
month = "5",
language = "English",
volume = "25",
pages = "2429--2434",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 C",

}

TY - JOUR

T1 - Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer

AU - Hotta, Katsuyuki

AU - Takigawa, Nagio

AU - Kiura, Katsuyuki

AU - Tabata, Masahiro

AU - Umemura, Shigeki

AU - Ogino, Atsuko

AU - Uchida, Akiko

AU - Bessho, Akihiro

AU - Segawa, Yoshihiko

AU - Shinkai, Tetsu

AU - Nogami, Naoyuki

AU - Harita, Shingo

AU - Okimoto, Niro

AU - Ueoka, Hiroshi

AU - Tanimoto, Mitsune

PY - 2005/5

Y1 - 2005/5

N2 - Background: Combination chemotherapy of irinotecan and amrubicin for advanced non-small cell lung cancer (NSCLC) has not been fully evaluated. To determine the maximum-tolerated dose (MTD), a phase I study in patients with advanced NSCLC was conducted. Materials and Methods: Patients with stage IIIB/IV NSCLC were enrolled in this study. Both patients with and without prior chemotherapy were also eligible. The drugs were administered on days 1 and 8, every 3 weeks. The starting doses of irinotecan and amrubicin were 60 and 35 mg/m2, respectively. Results: Nineteen patients received a total of 53 courses. Grade 4 neutropenia was observed in 23% of courses. Anaemia and thrombocytopenia were generally mild. Grade 3 febrile neutropenia occurred in 5 courses. Other grade 3 or greater non-haematological toxicities were observed in only 4 out of 52 courses (grade 3 infection and hyponatremia). The maximum-tolerated doses (MTDs) of irinotecan and amrubicin were 100 and 45 mg/m , respectively. Objective response was obtained in 2 patients (10.5%), who had received prior chemotherapy. Conclusion: This combination was well tolerated, but produced only a modest anti-tumour effect for advanced NSCLC. Further investigation into the role of this regimen as a salvage chemotherapy may be warranted in relapsed patients.

AB - Background: Combination chemotherapy of irinotecan and amrubicin for advanced non-small cell lung cancer (NSCLC) has not been fully evaluated. To determine the maximum-tolerated dose (MTD), a phase I study in patients with advanced NSCLC was conducted. Materials and Methods: Patients with stage IIIB/IV NSCLC were enrolled in this study. Both patients with and without prior chemotherapy were also eligible. The drugs were administered on days 1 and 8, every 3 weeks. The starting doses of irinotecan and amrubicin were 60 and 35 mg/m2, respectively. Results: Nineteen patients received a total of 53 courses. Grade 4 neutropenia was observed in 23% of courses. Anaemia and thrombocytopenia were generally mild. Grade 3 febrile neutropenia occurred in 5 courses. Other grade 3 or greater non-haematological toxicities were observed in only 4 out of 52 courses (grade 3 infection and hyponatremia). The maximum-tolerated doses (MTDs) of irinotecan and amrubicin were 100 and 45 mg/m , respectively. Objective response was obtained in 2 patients (10.5%), who had received prior chemotherapy. Conclusion: This combination was well tolerated, but produced only a modest anti-tumour effect for advanced NSCLC. Further investigation into the role of this regimen as a salvage chemotherapy may be warranted in relapsed patients.

KW - Amrubicin

KW - Irinotecan

KW - Non-platinum regimen

KW - Non-small cell lung cancer

KW - Phase I study

KW - Topoisomerase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=22944441618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22944441618&partnerID=8YFLogxK

M3 - Article

C2 - 16080470

AN - SCOPUS:22944441618

VL - 25

SP - 2429

EP - 2434

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 C

ER -